Glucagon-like peptide-1 receptor agonists (GLP-1s) have shown tremendous promise at controlling diabetes, and causing weight loss, and increasingly are being shown to reduce the burden of cardiovascular disease and other chronic conditions. While there is significant clinical promise and indications continue to accumulate, the costs of these treatments present coverage challenges to insurers and employers, who are increasingly limiting access and providing barriers to patients. These barriers may interact with racial disparities present for many of these conditions. The panel will tackle the issue of health equity of GLP1s, presenting diverse perspectives from employers, clinicians, and pharmaceutical manufacturers.
Panelists:
Shantanu Nundy, MD
EVP Care Delivery and Chief Health Officer, Accolade
Shantanu Nundy is a physician, entrepreneur, and technologist who is passionate about reinventing healthcare for all. He currently serves as EVP of Care Delivery and Chief Health Officer of Accolade, overseeing the company’s clinical strategy and physician-led advocacy services for millions of members and their families. Shantanu is a passionate champion for health equity, coauthoring the Quintuple Aim in JAMA and how employers can advance health equity in Harvard Business Review. Shantanu is also the author of the book “Care After Covid: What the Pandemic Revealed is Broken in Healthcare and How to Reinvent It.” He continues to practice primary care at Neighborhood Health, a federally qualified health center in greater Washington, DC. He also serves as a lecturer in health policy at the George Washington Milken Institute for Public Health and as an advisor to the World Bank Group on digital health and innovation. He completed my undergraduate studies at MIT, MD from Johns Hopkins, and MBA from the University of Chicago.
Gregory Daniel, PhD, MPH
Vice President & Head of Global Public Policy, Eli Lilly and Company
Gregory Daniel, PhD, MPH is Vice President, Global Public Policy at Eli Lilly and Company. Greg has led the Global Public Policy group, which is responsible for proactively identifying, assessing, and developing public policies in areas such as prescription drug access, affordability and innovation, global value-based healthcare, health equity, and other high priority policy areas. Greg also leads external policy engagement, policy research prioritization, and develops partnerships with academic groups, think-tanks, and other policy research organizations. He is also currently the Editor-in-Chief of Therapeutic Innovation and Regulatory Science (TIRS), the scientific journal of DIA. Greg also serves on the Board of Directors and is Past President for the Innovation in Value Initiative (IVI) Foundation.
Prior to joining Eli Lilly, Greg held the positions of Head of US Healthcare Policy at Edwards Lifesciences; Deputy Center Director and Clinical Professor at the Duke-Margolis Center for Health Policy; Fellow and Managing Director in the Center for Health Policy at the Brookings Institution; and Vice President, Government and Academic Research at HealthCore (subsidiary of Anthem).
Greg received his PhD in pharmaceutical economics, policy and outcomes from the University of Arizona, and an MPH focused in biostatistics, MS, and BS in Pharmacy all from The Ohio State University.
Katey Bey
Global Head, Total Rewards
Katey Bey is the Global Head of Total Rewards at Sedgwick where she focuses on the strategic leadership of their total rewards offering and colleague experience. Katey has spent the bulk of her career in the global Total Reward space specializing in designing, implementing, and managing benefits, compensation, and rewards programs.
Moderator:
Joseph Levy, PhD
Assistant Professor
Johns Hopkins Bloomberg School of Public Health
Conversations on the Business of Health
Webinar Series
This event is part of a larger series on 'Conversations on the Business of Health,' which will be one-hour webinars that will engage leaders in business and academia. We will explore questions such as:
- Should companies invest in their employees’ health?
- Are companies responsible for the health consequences of their products?
- Will artificial intelligence actually advance health?
- How can business offer healthcare in novel settings?
Moderated by faculty members and jointly hosted by the Bloomberg School of Public Health, the Carey Business School, the School of Nursing, and the School of Medicine, the series is open to all. Indeed, we invite you to spread the word as we seek participants both inside and outside of Johns Hopkins, including the business world.
Seminars will be on a Friday from noon to 1 p.m. unless otherwise noted.